Amphastar Pharmaceuticals (AMPH) Downgraded by Zacks Investment Research to Strong Sell

Amphastar Pharmaceuticals} stock has undergone multiple analysts rating changes in the recent past.  Amphastar Pharmaceuticals Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Strong Sell. The analysts previously had rating of Hold.

View More Amphastar Pharmaceuticals (AMPH) Downgraded by Zacks Investment Research to Strong Sell

Earnings Report: Here’s what to expect from Amphastar Pharmaceuticals (NASDAQ:AMPH)

Earnings results for Amphastar Pharmaceuticals , Analyst Opinion on Amphastar Pharmaceuticals , Earnings and Valuation of (NASDAQ:AMPH), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings Report: Here’s what to expect from Amphastar Pharmaceuticals (NASDAQ:AMPH)

Is it time to Buy before this week’s earning report Amphastar Pharmaceuticals (NASDAQ:AMPH)

Earnings results for Amphastar Pharmaceuticals , Analyst Opinion on Amphastar Pharmaceuticals , Earnings and Valuation of (NASDAQ:AMPH), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Is it time to Buy before this week’s earning report Amphastar Pharmaceuticals (NASDAQ:AMPH)

Is it time to Buy before this week’s earning report Amphastar Pharmaceuticals (NASDAQ:AMPH)

Earnings results for Amphastar Pharmaceuticals , Analyst Opinion on Amphastar Pharmaceuticals , Earnings and Valuation of (NASDAQ:AMPH), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Is it time to Buy before this week’s earning report Amphastar Pharmaceuticals (NASDAQ:AMPH)

Earnings Scorecard & Analyst Reports for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Earnings results for Amphastar Pharmaceuticals , Analyst Opinion on Amphastar Pharmaceuticals , Earnings and Valuation of (NASDAQ:AMPH), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings Scorecard & Analyst Reports for Amphastar Pharmaceuticals (NASDAQ:AMPH)